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Abstract
Infliximab (IFX) is administered intravenously using weight-based dosing (5 mg/kg) in inflammatory bowel disease (IBD)
patients. Our hypothesis is that especially young children need a more intensive treatment regimen than the current weight-
based dose administration. We aimed to assess IFX pharmacokinetics (PK), based on existing therapeutic drug monitoring
(TDM) data in IBD patients < 10 years. TDM data were collected retrospectively in 14 centres. Children treated with IFX were
included if IFX was started as IBD treatment at age < 10 years (young patients, YP) and PK data were available. Older IBD
patients aged 10–18 years were used as controls (older patients, OP). Two hundred and fifteen paediatric inflammatory bowel
disease (PIBD) patients were eligible for the study (110 < 10 year; 105 ≥ 10 years). Median age was 8.3 years (IQR 6.9–8.9) in
YP compared with 14.3 years (IQR 12.8–15.6) in OP at the start of IFX. At the start of maintenance treatment, 72% of YP had
trough levels below therapeutic range (< 5.4 μg/mL). After 1 year of scheduled IFX maintenance treatment, YP required a
significantly higher dose per 8 weeks compared with OP (YP; 9.0 mg/kg (IQR 5.0–12.9) vs. OP; 5.5 mg/kg (IQR 5.0–9.3); p <
0.001). The chance to develop antibodies to infliximab was relatively lower in OP than YP (0.329 (95% CI − 1.2 to − 1.01); p <
0.001), while the overall duration of response to IFX was not significantly different (after 2 years 53% (n = 29) in YP vs. 58%
(n = 45) in OP; p = 0.56).
Conclusion: Intensification of the induction scheme is suggested for PIBD patients aged < 10 years.
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What is Known?
•Infliximab trough levels of paediatric IBD patients are influenced by several factors as dosing scheme, antibodies and inflammatory markers.
•In 4.5–30% of the paediatric IBD patients, infliximab treatment was stopped within the first year.
What is New?
•The majority of young PIBD (< 10 years) have inadequate IFX trough levels at the start of maintenance treatment.
•Young PIBD patients (< 10 years) were in need of a more intensive treatment regimen compared with older paediatric patients during 1 year of IFX
treatment.
•The chance to develop antibodies to infliximab was relatively higher in young PIBD patients (< 10 years).
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Abbreviations
IBD Inflammatory bowel disease
IFX Infliximab
OP Older patients; patients ≥ 10 years of age
PD Pharmacodynamic
PIBD Paediatric inflammatory bowel disease
PK Pharmacokinetic
TDM Therapeutic drug monitoring
TNF-α Tumour necrosis factor alpha
VEO-IBD Very early-onset inflammatory bowel disease
YP Young patients; patients < 10 years of age
Introduction
Treatment options for inflammatory bowel disease (IBD) rad-
ically changed after the introduction of monoclonal antibodies
to tumour necrosis factor alpha (TNF-α). Infliximab (IFX),
the first developed anti-TNF-α biological agent [1], is admin-
istered intravenously in a weight-based dose (5 mg/kg) in both
paediatric and adult patients during induction (infusion at
weeks 0, 2 and 6) and maintenance phase (every 8 weeks) [2].
Contradictory to this dosing scheme, Dotan et al. showed a
nonlinear correlation between higher body weight and IFX
clearance. Therefore, in lower body weight patients, it would
be expected to have a lower drug exposure at all times than
patients with a higher body weight after administration of
5 mg/kg [3]. In paediatric patients, a 25–40% lower drug
exposure was found compared with adults [4, 5]. This implies
that paediatric patients with low body weight are more likely
to be underdosed.
However, even within the paediatric IBD (PIBD) popula-
tion, response rates may differ significantly [4, 6–8]. Kelsen
et al. [9] found that paediatric CD patients 7 years or younger
showed lower IFX response rates and were less likely to con-
tinue IFX therapy compared with older paediatric CD patients
[10].
Besides weight, developmental changes in body composi-
tion are known to affect absorption, distribution, metabolism
and excretion of a biological agent which explains a larger
variability of IFX disposition [4, 11, 12]. Moreover, pharma-
cokinetic (PK) population studies in older paediatric and adult
IBD patients show that inflammatory burden, serum albumin
levels, concomitant immunomodulators and presence of anti-
bodies to infliximab (ATIs) [3, 13, 14] affect drug clearance.
However, data on IFX trough levels within this special
population are still limited. For this reason, the primary aim
of this study was to investigate the pharmacological response
to IFX, based on existing therapeutic drug monitoring (TDM)
data, in young (< 10 years) PIBD patients and to compare
these with data of older (≥ 10 years) PIBD patients.
Methods
Study design and patient management
In this retrospective case-controlled study, data of children
treated with IFX between 2004 and 2019 were collected be-
tween 2015 and 2019 from centres in Europe and Canada as a
PIBD Porto group of ESPGHAN initiative. For the young
patient (YP) group, PIBD patients were eligible if IFX treat-
ment was started for active disease before age of 10 years.
These data were compared with a control group of paediatric
IFX treated IBD patients above age of 10. This cut-off was
based on age groups classified by the Paris classification [15].
OP were selected based on the time period IFX treatment was
started. Patients were excluded if data on IFX dosing or levels
weremissing or if a patient was diagnosed with a monogenetic
disease. Investigators from participating centres were asked to
enter all patient information into Castor, an electronic data
capturing tool (Amsterdam, the Netherlands). Recorded an-
thropometric and longitudinal data on clinical parameters
and PK/pharmacodynamic (PD) parameters, of YP (< 10 years
at time of IFX initiation) and older patients (OP; ≥ 10 years at
time of IFX initiation), were compared. IFX trough levels
could be collected pro- or reactively.
Outcome measures and definitions
Clinical disease activity was defined by Physician Global
Assessment (PGA) scores. Quiescent disease and clinical re-
mission were defined as 0, if in the last week the patient had
minimal or no symptoms thought to be secondary to IBD,
mild disease as 1 (mild recurring or persistent symptoms
thought to be secondary to IBD), moderate disease as 2 (mod-
erate or combinations of mild and moderate recurring or per-
sistent symptoms secondary to IBD) and severe as 3 (severe or
combinations of moderate and severe recurring or persistent
symptoms thought to be due to IBD) [16]. Drug levels were
defined as subtherapeutic if IFX serum trough levels were <
29 μg/mL at 2 weeks, < 18 μg/mL at 6 weeks [17] and <
5.4 μg/mL at 14 weeks after start IFX treatment [18, 19]. A
second reference cut-off < 3.1 μg/mL for maintenance treat-
ment in adult patients was used to compare our paediatric
patients with adult patients [14, 20]. Treatment intensification
by dose intensification and/or interval adjustment was done
based on physician’s discretion. Loss of response due to PK
was defined as having low trough levels despite adequate
dosing. Loss of response due to pharmacodynamics was de-
fined as loss of response to therapy despite adequate trough
levels (trough level ≥ 5.4 μg/mL). Loss of response due to
immunogenicity was defined as having low trough levels
and proven presence of ATI. Primary nonresponse was de-
fined as equal or increased PGA score after completion of
induction therapy (14 weeks). Secondary loss of response
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was defined as recurring symptoms after initial clinical benefit
(increased PGA score) resulting in treatment change [21].
ATIs were defined as positive if antibodies were measured
above the cut-off point of the specific assays used
(Online Resource 1). In all centres, ESR levels were deter-
mined with the Westgren method.
Primary outcome was the comparison of dosing and treat-
ment intervals between age groups after 1 year of IFX treat-
ment. Secondary outcomes were the following: (1) Evaluation
of trough levels during induction (weeks 2 and 6) and main-
tenance treatment (weeks 14, 52 and 104) in YP with proac-
tively collected trough levels, (2) Primary nonresponse to IFX
treatment, (3) Clinical remission 1 year after start of IFX treat-
ment, (4) Identification of independent clinical predictors
influencing IFX trough levels, (5) ATI development within
52 weeks, (6) IFX treatment failure at 52 weeks.
Statistical analysis
Continuous variables, normally distributed, were reported as
means and standard deviations and compared with the t test.
Continuous variables not following normal distribution were
analysed by the Mann-Whitney U test and presented as me-
dians and interquartile range (IQR). Ordinal variables were
analysed by the Kruskal-Wallis test. Categorical variables
were presented as absolute frequencies and percentages and
compared by the χ2 test or Fisher exact test. Three different
linear mixed models were constructed, the first to evaluate
trough levels during induction and maintenance treatment,
the second to describe the evolution of trough levels over time
and identify independent predictors affecting this evolution
and a third model to evaluate differences in ATI levels
(Online Resource 2). A Kaplan-Meier survival analysis was
performed to evaluate duration of IFX treatment. The signif-
icance level was set to 0.05; no corrections were performed for
multiple testing. Calculations were performed using IBM
SPSS Statistics 24.0 (IBM Corp, Armonk, NY).
Results
Baseline characteristics
Two hundred and fifteen PIBD patients were enrolled in the
study, 110 young IBD patients (< 10 years), whereof 14/110
were very early-onset inflammatory bowel disease (VEO-
IBD) patients (< 6 years), and 105 older IBD patients (≥ 10
and < 18 years) at initiation of IFX treatment. Median age at
the start of IFX treatment was 8.3 (IQR 6.9–8.9) years in YP,
while this was 14.3 (IQR 12.8–15.6) years in OP. In the YP
group, fewer patients (66/110, 60%) were diagnosed with CD,
compared with the OP group (81/105, 77%); p = 0.024).
Inflammatory markers and disease location were comparable
in both age groups at the start of IFX treatment (Table 1).
Despite IFX was started with a median dose of 5 mg/kg
(IQR5-5) in both groups, YP at start received a significant
higher dose (p = 0.015). Seventy-seven percent (85/110) of
YP and 90% (95/105) of OP received 5 mg/kg. In 11% (12/
110) of YP, already a dose of ≥ 8mg/kg was started, while this
was done in 3% (3/105) of OP. YP were included in 14 dif-
ferent centres (median 6 [IQR 4–8] patients per centre), and
OP were included in 9 centres (median 10 [IQR-3-10]).
In multivariate analyses, IFX trough levels were not signif-
icantly different between UC and CD patients; thus, the data
of patients with both diagnoses are pooled (β − 0.29; 95% CI
− 0.640 to 0.059, p = 0.101); Table 2). In addition, a separate
analysis for UC and CD patients is shown in Table 3.
YP received a more intensive IFX treatment schedule
compared with OP after 1 year of IFX
In the YP group, 12/110 (11%) showed primary nonresponse
to IFX treatment compared with 5/105 (5%) OP (p = 0.133).
In these patients, IFX already was discontinued during induc-
tion in a comparable number of 9/110 (8%) YP and 3/105
(3%) OP (p = 0.09). In YP, IFX was discontinued because of
immunogenicity (n = 3), PK (n = 2), PD (n = 2) or other rea-
sons (n = 2), while in OP, this was related to pharmacodynam-
ics in all cases (n = 3).
After 1 year of scheduled IFX maintenance treatment, YP
required a significantly higher dose per 8 weeks compared
with OP (YP; 9.0 mg/kg (IQR 5.0–12.9) vs. OP; 5.5 mg/kg
(IQR 5.0–9.3); p < 0.001). This also was reflected in the num-
ber of patients on IFX receiving treatment escalation, 52/71
(73%) YP vs. 34/76 (45%) OP, p < 0.001 (Table 4).
Clinical remission at 1 year
In 94/110 (85%) YP and 79/105 (75%) OP, data of clinical
remission rate after 1 year were available. The number of
patients in clinical remission while still on IFX maintenance
was comparable (31/94 (33%) in YP vs. 34/79 (43%) in OP;
p = 0.174) for both groups after 1 year. However, within this
subgroup, significantly less YP were still receiving a weight
based 5 mg/kg IFX treatment scheduled every 8 weeks (8/31
(26%) of YP compared with 20/33 (59%) of OP; p = 0.007).
The proportion of YP patients in clinical remission was similar
in YP with a high dose at start (> 8 mg/kg) (3/11 (27%))
compared with patients started with standard dose (≤ 5 mg/kg;
22/69 (32%); p = 0.759). Proactively collected trough levels
did not result in a higher proportion of patients in clinical
remission. Ten of 44 patients with proactive collection were
in clinical remission at week 52 while this was the case for 20/
50 patients with reactively determined trough levels after start
IFX, p = 0.123.
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IFX trough levels are suboptimal at the start of
maintenance treatment in the majority of YP
In a subgroup (46/110) of YP, 414 trough levels were proac-
tively determined during follow-up; an overview of these
trough levels is shown in Table 5. At the start of maintenance
treatment (week 14), the median trough level in this group was
3.1 μg/mL (IQR 1–6.4). The percentage of YP with subther-
apeutic trough levels (< 5.4 μg/mL) was 72% (25/35). Even
according the lower target levels in adult literature, still 17/35
(49%) patients had a subtherapeutic level (< 3.1 μg/mL). YP
with a trough level < 5.4 μg/mL at week 14 significantly more
often developed ATI within the first year (16/18 patients),
compared with YP with trough levels ≥ 5.4 μg/mL at week
14 (8/17; p = 0.02). Out of the 917 IFX trough levels (proac-
tive and reactive) analysed in the whole cohort, 109 samples
were measured during IFX induction. Combined mean trough
levels of weeks 2 and 6 were comparable in YP (n = 86) com-
pared with OP (exp β − 0.15, 95% CI − 0.44 to 0.15; p =
0.323), although the number of levels drawn in OP (n = 23)
Table 1 Baseline characteristics of patients at start infliximab treatment
Total, n = 215 YP start IFX < 10
years of age, n = 110
OP start IFX ≥ 10 years
of age, n = 105
p value
Age at diagnosis in years (IQR) 9.22 (6.6–12.9) 6.71 (5.12–8.36) 12.93 (11.65–14.55) < 0.001
Age at start treatment in years (IQR) 9.72 (8.26–14.0) 8.32 (6.95–8.93) 14.32 (12.79–15.61) < 0.001
Sex (%) Male 122 (57%) 58 (53%) 64 (61%) 0.224
BSA (IQR) n = 171 1.53 (0.90–1.48) 0.90 (0.78–1.02). 1.52 (1.29–1.69) < 0.001
Diagnosis (%) Crohn’s disease 147 (69%) 66 (60%) 81 (77%) 0.024
Ulcerative colitis 50 (23%) 33 (30%) 17 (16%)
IBD unclassified 18 (8%) 11 (10%) 7 (7%)
Ethnicity (%) Afro-Caribbean 19 (9%) 8 (7%) 10 (10%) 0.388
Arab 33 (15%) 14 (12.8%) 19 (18%)
Asian 1 (1%) 1 (0.9%) 0 (0%)
Caucasian 149 (70%) 79 (73%) 72 (69%)
Other 11 (5%) 8 (7.3%) 3 (3%)
TPMT status (%) Homozygous 78 (36%) 46 (42%) 32 (30%) 0.295
Heterozygous 11 (5%) 4 (4%) 7 (7%)
Unknown 126 (59%) 60 (54%) 66 (63%)
ESR (mm/h) (IQR) n = 161 28 (19–42) 30 (20–42) 27 (16–49) 0.654
CRP (mg/L) (IQR) n = 180 11 (3.4–40.5) 10 (3–25) 20 (4–52) 0.066
Albumin (g/L) (IQR) n = 177 37 (33–42) 35 (31.2–39.6) 40 (34–43) 0.095
Clinical disease activity (%) Quiescent 0 4 (2%) 3 (3%) 1 (1%) 0.659
Mild 1 15 (11%) 11 (13%) 8 (12%)
Moderate 2 80 (37%) 41 (48%) 38 (47%)
Severe 3 65 (30%) 31 (36%) 34 (42%)
Median start dose (mg/kg) (IQR) 5 (5–5) 5 (5–5) 5 (5–5) 0.015
Paris classification Age A1a 115 (54%) 110 (100%) 5 (5%) < 0.001
A1b 100 (46%) 100 (95%)
For CD patients Location L1 15 (13%) 7 (14%) 8 (11%) 0.071
L2 37 (31%) 21 (43%) 16 (23%)
L3 68 (56%) 21 (43%) 45 (65%)
L4a 31 (26%) 14 (21%) 17 (21%)
L4b 5 (4%) 3 (5%) 2 (3%)
Behaviour B1 100 (83%) 38 (76%) 60 (87%) 0.126
B2 11 (9%) 5 (10%) 6 (9%)
B3 7 (5%) 6 (12%) 1 (1%)
B2B3 3 (2%) 1 (2%) 2 (3%)
Perianal disease (%) 43 (36%) 22 (43%) 21 (31%)
Growth delay (%) 43 (37%) 19 (37%) 24 (36%)
For UC and IBD-U patients Extent 1 1 (2%) – 1 (5%) 0.747
2 4 (9%) 2 (9%) 2 (8%)
3 5 (11%) 3 (14%) 2 (8%)
4 36 (78%) 17 (77%) 19 (79%)
Ever severe (%) 38 (83%) 17 (79%) 21 (88%) 0.361
p values are from Fisher’s exact test for categorical variables and fromKruskal-Wallis or Mann-WhitneyU test for continuous variables. p values < 0.05
were considered as significant
Abbreviations: YP young patients,OP older patients, TPMT thiopurine methyltransferase, ESR erythrocyte sedimentation, CRP C-reactive protein, BSA
body surface area, IQR interquartile range, % percentage
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is low. Duringmaintenance treatment, mean IFX trough levels
in YP (n = 536) and OP (n = 272) were similar (exp β − .11,
95% CI − 0.52 to 0.30; p = 0.593).
Predictors of IFX trough levels during IFX treatment
Multivariate analyses of all trough levels (measured both pro-
actively and reactively) of both age groups showed a signifi-
cant association between higher IFX trough levels and a more
intensive treatment regimen, accounted to shorter intervals (β
− 0.006; 95% CI 0.010 to − 0.001; p = 0.011). ATI positivity
was negatively associated with IFX trough levels (β − 0.681;
95% CI 0.446 to 0.914; p < 0.001). Age at the start of therapy
(β − .013; 95% CI − 0.063 to 0.038; p = 0.613) was not sig-
nificantly associated with IFX trough levels (Table 2).
Significantly higher risk to develop ATI in YP
compared with OP
Taken in account repeated measurement in multivariate anal-
ysis, the chance to develop ATI was relatively 0.329 (95% CI
1.2 to 1.01; p < 0.001) times lower in OP than YP. In addition,
use of immunomodulators reduced the chance to develop
ATIs 1.4 (95% CI − 0.31 to 0.39; p < 0.001) times more fre-
quently. Despite more immunogenicity in YP during treat-
ment, durability on IFX was not significantly different be-
tween the different age groups (p = 0.444). Seventy-seven per-
cent of YP were still on IFX treatment after 1 year of follow-
up (Fig. 1). This number decreased to 53% after 2 years.
Median durability on IFX was 114 weeks in the YP group,
compared with 160 weeks in the OP group.
Table 3 Outcome measures split out for diagnosis CD and UC/IBDU. (A) Proportion of patients with treatment changes. (B) Median trough levels
(IQR) during induction and maintenance treatment at 2, 6, 14 and 52 weeks
(A)




p value Older CD patients Older UC /IBDU
patients
p value





33/45 (73%) 18/24 (75%) 0.881 27/61 (44%) 6/12 (50%) 0.715
Dose intensification, n (%) 27/45 (39%) 15/24 (63%) 0.839 16/61 (29%) 6/12 (50%) 0.101
Interval adjustment, n (%) 28/45 (62%) 11/23 (48%) 0.256 20/62 (32%) 3/12 (25%) 0.619
Clinical remission with IFX,
n (%)
19/57 (33%) 12/37 (32%) 0.928 27/58 (47%) 7/21 (33%) 0.295
(B)
Median trough levels during induction and
maintenance treatment Young CD patients
Young UC/IBDU
patients p value
Trough levels at week 2 μg/mL (IQR) 10.1 (7.9–16.1) (n = 21) 15.2 (10.4–18.8) (n = 9) 0.808
Trough levels at week 6 μg/mL (IQR)
7.2 (3.8–12.7) (n = 23)
10.4 (0.75–12.5) (n = 14)
0.487
Trough levels at week 14 μg/mL (IQR)
3.1 (1–6.0) (n = 25)
2.9 (0.0–11.5) (n = 10)
0.584
Trough levels at week 52 μg/mL (IQR)
6.4 (2.1–10.8) (n = 13)
1.2 (0.0–1.9) (n = 5)
0.035
p values < 0.05 were considered as significant
Abbreviations: CD Crohn’s disease, UC ulcerative colitis, IFX infliximab, IQR Inter quartile range
Table 2 Predictors of infliximab trough level
B p value 95% CI
Intercept 0.419 0.317 (− 0.410 to 1.249)
Reactive sample collection − 0.235 0.345 (− 0.672 to 0.034)
Time in days < − 0.001 0.767 (− 0.003 to < 0.001)
Male sex − 0.024 0.882 (− 0.351 to 0.303)
Diagnose CD − 0.291 0.101 (− 0.640 to 0.059)
Age at diagnosis − 0.013 0.613 (− 0.063 to 0.038)
Albumin (g/L) < − 0.001 0.938 (− 0.011 to 0.012)
CRP (mg/L) 0.003 0.379 (− 0.011 to 0.004)
ESR (mm/h) − 0.004 0.270 (− 0.012 to < 0.004)
Clinical disease activity − 0.014 0.845 (− 0.153 to 0.125)
ATI positive − 0.681 < 0.001 (0.446 to 0.914)
Immunomodulator use − 0.149 0.140 (− 0.348 to 0.049)
Dose (mg/kg) 0.050 0.051 (< 0.001 to 0.100)
Interval (days) − 0.006 0.011 (− 0.010 to − 0.001)
Linear mixed model analysis is performed to investigate the influence of
different predictors on IFX trough levels. p values < 0.05 were considered
as significant
Abbreviations: B beta, sig. significant, CI confidence interval, CRP C-
reactive protein, BSA body surface area, ESR erythrocyte sedimentation
rate, IFX infliximab, ATI antibody to infliximab
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Discussion
We analysed data of 622 IFX trough levels measured
among 110 young (< 10 years) PIBD patients. Moreover,
to examine differences in age groups, we compared young
to older (≥ 10 years) PIBD patients (105 patients, 295 IFX
trough levels). This resulted in a unique overview of clin-
ical efficacy and trough levels of IFX treatment in very
young PIBD patients.
In our study, 23% of young PIBD patients had primary
nonresponse or secondary loss of response within the first
year. This is in line with previous literature, where in 4.5–
30% of older PIBD patients, IFX was discontinued [7, 10,
22]. On the other hand, a retrospective study in children ≤
7 years by Kelsen et al. (n = 33, 61% CD; median age at start
5.6; collected between 1999 and 2011) [9] found a very high
loss of response to IFX treatment of 64% in their population.
This difference in response rate between our study and Kelsen
et al. may be explained by an increased use of early TDM in
clinical practice over time. The current ECCO ESPGHAN
paediatric CD guideline recommends evaluation of IFX dos-
ing preceding the fourth infusion [1]. Early TDM is associated
with therapy enhancement and sustained response to IFX and
decrease of immunogenicity [14, 19]. In contrast, YP with
proactively collected trough levels in our cohort were not sig-
nificantly more often in clinical remission after 52 weeks.
In 97% of YP, trough levels < 29 μg/mL were found, a cut-
off at 2 weeks for predicting treatment success according to
Table 5 Infliximab trough levels routinely measured in young patients







IFX week 2 (n = 30) 5 mg/kg (IQR 5–5) 12.5 μg/mL (8.2–17.5) 29 μg/mL† 97% 27%
IFX week 6 (n = 37) 5 mg/kg (IQR 5–5.1) 8.2 μg/mL (3.1–12.5) 18 μg/mL† 87% 40%
IFX week 14 (n = 35) 5 mg/kg (IQR 5–8.7) 3.1 μg/mL (1–6.4) 5.4 μg/mL‡ 72% 43%
52 weeks (n = 18) 7.5 mg/kg (IQR 5–10) 4.4 μg/mL (0.8–6.3) 5.4 μg/mL‡ 50% 42%
104 weeks (n = 8) 6.5 mg/kg (IQR 5–10) 5.5 μg/mL (2.8–8.7) 5.4 μg/mL‡ 38% 58%
Trough levels of a subgroup of YP (young patients; < 10 years) (n = 46) were routinely measured. Median trough levels (μg/mL), recommended range
and clinical remission (%), are shown at 2, 6, 14, 52 and 104 weeks
Abbreviations: IFX infliximab, IQR inter quartile range, TL trough level
†Clarkston K, Tsai YT, Jackson K, Rosen MJ, Denson LA, Minar P (2019) Development of Infliximab Target Concentrations During Induction in
Pediatric Crohn Disease Patients. J Pediatr Gastroenterol Nutr 69:68–74
‡ van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S (2018) Higher Infliximab Trough Levels Are Associated With
Better Outcome in Paediatric Patients With Inflammatory Bowel Disease. J Crohns Colitis 12:1316–1325; van Hoeve K, Hoffman I, Vermeire S (2018)
Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. Expert Opin Drug Saf 17:185–196
Table 4 Treatment strategy by
1 year after start of infliximab YP start IFX
< 10 years of age
OP start IFX
≥ 10 years of age
p value
Patients on IFX at 52 weeks (n) 71/94 76/95
Patients received treatment escalation, n (%) 52/71 (73%) 34/76 (45%) < 0.001
Dose intensification, n (%) 42/71 (61%) 24/76 (32%) 0.001
Interval adjustment, n (%) 39/71 (57%) 24/76 (32%) 0.002
Mg/kg per 8 week interval at 52 weeks; median
(IQR)
9.0 (5–12.9) 5.5 (5–9.3) < 0.001
Median interval in days (IQR) 49 (39–56) 56 (49–57) 0.002
Median dose (mg/kg) (IQR) (not corrected for
interval in weeks)
8 (5–10) 5 (5–8) 0.002
Patients lost to follow-up at week 52 94/110 (15%) 95/105 (10%)
Primary nonresponse IFX was defined as equal or increased PGA score after completion of induction therapy
(14 weeks). p values < 0.05 were considered as significant
Abbreviation: YP young patients, OP older patients, IQR interquartile range, % percentage
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Clarkson et al. [17], and at the start of maintenance treatment,
suboptimal trough levels (< 5.4 μg/mL) were measured in the
majority (72%) of YP patients [18, 19]. Moreover, if we com-
pare the percentage of patients with IFX levels < 3.1 μg/mL in
YP (49%), this is almost twice as high as described in previous
published litrature of OP (25%) [23].
Furthermore, we found significantly more YP needed treat-
ment optimisation to achieve clinical remission compared
with OP. This is in line with the results of both Dotan et al.
and Xu et al. who showed a nonlinear correlation between
body weight and IFX clearance [3, 4]. De Bruyn et al. [7]
showed that patients diagnosed with IBD < 10 years had an
increased change of IFX treatment optimisation. However,
this did not account for children treated with IFX < 10 years
or above. Nonetheless, it is clear that further studies on how to
optimize IFX dosing in young PIBD patients are required.
In multivariate analysis, our data showed YP tended to
develop ATIs more frequently than OP. In line with other
studies in PIBD [3, 6, 13, 14, 24], a positive association
between IFX trough levels and shorter interval length was
found. As expected, within our cohort of PIBD patients,
ATI positivity was associated with lower IFX trough
levels. Previous studies demonstrated that low IFX levels
were associated with immunogenicity and increased ATI
formation [8, 25]. YP in our study who had subtherapeu-
tic trough levels during induction, which could be related
to a significantly higher proportion of ATI positive pa-
tients. In contrast to recent literature [13, 26], we did
not find a correlation between use of immunomodulator
(in particular thiopurines) combination therapy and higher
trough levels. On the other hand, in line with other stud-
ies, our data did show a significant decrease of immuno-
genicity during combination therapy in YP as well as in
OP [27]. PIBD subtype had a nonsignificant effect on IFX
trough levels; therefore, it was not possible to further dis-
tinguish patients based on disease subtype. We could not
determine a direct influence of age on IFX trough levels.
This might suggest that it is feasible in YP to reach ade-
quate IFX trough levels, as long as other factors such as
immunogenicity can be prevented. As such, it seems even
more important that YP are adequately dosed from start of
IFX. In addition, we did not find a significant difference
in the group of YP receiving proactive TDM, although
previous studies showed that frequent proactive TDM
could be beneficial to further individualize therapeutic
strategies in these patients [6, 28].
Since several other patient factors influence trough levels,
it is not possible to give a patient specific dose recommenda-
tion. Therefore, the development of a PK model for young
patients would be of additional value. Simulation of dosing
and treatment schemes based on existing PK data would help
to further optimize dosing. Treatment escalation at the start of
IFX treatment could lead to supra therapeutic trough levels
which might lead to increased immunosuppression or toxicity.
However, this has not been described in adult IBD studies,
where high target IFX levels (median 10 μg/mL) did not show
an increased rate of infections or other adverse events [29, 30].
Besides, high target levels (up to 15 μg/mL) seem not only
safe but also beneficial in achieving mucosal healing [29] or
remission in (paediatric) IBD patients with perianal fistulising
CD [30–33].
Clear strengths of the study were the relatively large
number of YP, the number of IFX trough levels (n = 622)
and a long follow-up period (median 798 days) of this
relatively small YP population. However, a limitation of
this study is its retrospective design. Data collection and
TDM were not performed in a standardized manner (pro-
and reactively) which increased the risk for bias.
However, a prospective study in this special population
will require a very long time. As a consequence of this
design, not all patients started with the same dose and
were we unable to compare trough levels of YP and OP
at the important time point of week 14. Moreover, IFX
























tFig. 1 Duration on IFX
treatment. Kaplan-Meier survival
analysis of duration in days at IFX
treatment for YP; young patients
< 10 years of age and OP; older
patients ≥ 10 years of age (p =
0.562)
1941Eur J Pediatr (2020) 179:1935–1944
assays at the local centres. Comparison of different meth-
odologies in Europe demonstrated significant concor-
dance. Therefore, we estimate this effect to be marginal
[34, 35]. Despite concordance between ATI assays, dif-
ferent measurement units made it impossible to compare
the effect of ATI levels on a continuous scale [36].
Moreover, if the IFX serum concentration could be detect-
ed in a serum sample, ATIs were usually not determined.
This may have resulted in a negligible underestimation of
the absolute number of ATI positive patients in both
groups.
Evaluation of disease activity was limited. PGA was used
to evaluate clinical disease activity while endoscopic data and
faecal calprotectin levels were missing. Lastly, only 13% of
the YP were VEO-IBD patients (< 6 years) which makes it
impossible to draw conclusions for this very small but extra
vulnerable part of the population in whom IFX is only avail-
able for off-label use.
Conclusion
Our data suggest that up front intensification of the IFX in-
duction scheme in PIBD patients under age of 10 is warranted.
Development of a PK model predicting the optimal dose and
dosing schemes per patient will be of additional value to con-
firm and specify our findings. Besides, validation in prospec-
tive trials is crucial to further optimize the treatment regimen
for young PIBD patients.
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